Table 6.
Descriptive statistics on the analyzed variables in separate groups of patients.
| Value | 1 (Mean ± SD) |
2 (Mean ± SD) |
|---|---|---|
| DUP | 19.7 ± 19.92 | 32.47 ± 35.17 |
| Number of hospitalizations (QH) | 64.95 ± 31.07 | 63.88 ± 37.26 |
| Age of onset (AE) | 18.6 ± 3.07 | 19 ± 4.61 |
| Number of episodes (QE) | 3 ± 3.4 | 3.41 ± 3.97 |
| Hospitalization length (HL) | 3.49 ± 5.93 | 3.33 ± 4.79 |
| PANSS pos_1 | 21.8 ± 4.73 | 19.71 ± 5.02 |
| PANSS neg_1 | 25.95 ± 6.03 | 26.65 ± 7.23 |
| PANSS dis_1 | 21 ± 5.53 | 19 ± 5.2 |
| PANSS exc_1 | 12.25 ± 4.92 | 13.65 ± 4.57 |
| PANSS emo_1 | 12.2 ± 3.49 | 13.29 ± 2.64 |
| PANSS pos_12 | 9 ± 2.22 | 8.94 ± 2.62 |
| PANSS neg_12 | 19.25 ± 4.88 | 15.81 ± 5.27 |
| PANSS dis_12 | 10.75 ± 3.32 | 9.13 ± 2.96 |
| PANSS exc_12 | 5.85 ± 3.05 | 5.81 ± 1.68 |
| PANSS emo_12 | 8.55 ± 2.76 | 8.13 ± 1.41 |
| BDI_1 | 11.4 ± 4.19 | 8.94 ± 4.56 |
| BDI_12 | 17.95 ± 5.12 | 13.18 ± 3.13 |
| Calgary_1 | 4.25 ± 2.17 | 3.24 ± 1.99 |
| Calgary_12 | 9.6 ± 2.68 | 7.29 ± 3 |
| CTQ_EN | 18.1 ± 3.92 | 15.76 ± 5.18 |
| CTQ_EA | 14.85 ± 3.88 | 13.12 ± 5.01 |
| CTQ_PN | 13.1 ± 4.73 | 10.47 ± 4.17 |
| CTQ_PA | 9.55 ± 3.36 | 9.06 ± 4.49 |
| CTQ_SA | 6.5 ± 3.5 | 5.94 ± 3.4 |
| CTQ_TOTAL | 62,08 ± 3.45 | 54,32 ± 3.21 |
| FT4_1 | 12.78 ± 3.68 | 12.68 ± 1.31 |
| FT3_1 | 5.09 ± 1.07 | 4.6 ± 0.99 |
| Drug dose1_1 | 12.55 ± 44.25 | 2.41 ± 2.64 |
| Chlorpromazine1_1 | 100.83 ± 82.8 | 76.47 ± 73.14 |
| Drug dose 1_12 | 69.85 ± 112.13 | 101.65 ± 147.92 |
| Chlorpromazine 1_12 | 360.09 ± 86.82 | 327.45 ± 116.21 |
| WBC × 103/µL_1 | 5.83 ± 1.4 | 6.36 ± 3.5 |
| NEUT × 103/µL_1 | 3.34 ± 1.16 | 3.79 ± 2.79 |
| LYMPH × 103/µL_1 | 1.95 ± 0.54 | 2.36 ± 0.59 |
| MONO × 103/µL_1 | 0.56 ± 0.18 | 0.58 ± 0.23 |
| RBC × 106/µL_1 | 4.72 ± 0.59 | 4.81 ± 0.64 |
| HGB g/dL_1 | 13.61 ± 2.2 | 14.16 ± 1.69 |
| HCT%_1 | 40.11 ± 5.24 | 41.99 ± 3.27 |
| MCV fL_1 | 85.04 ± 4.15 | 85.52 ± 6.17 |
| MCH pg_1 | 28.78 ± 2.02 | 29.67 ± 1.78 |
| MCHC g/dL_1 | 33.63 ± 1.29 | 33.99 ± 1.14 |
| RDW-SD fL_1 | 40.01 ± 3.04 | 39.57 ± 4.86 |
| RDW-CV_1 | 13.02 ± 1.22 | 12.72 ± 1.6 |
| PLT × 103/µL_1 | 247.15 ± 48.5 | 236.94 ± 83.91 |
| PDW fL_1 | 12 ± 2.1 | 12.2 ± 1.69 |
| MPV fL_1 | 10.36 ± 0.98 | 10.5 ± 1.01 |
| PLCR_1 | 27.58 ± 8.2 | 28.03 ± 6.25 |
| PCT_1 | 0.26 ± 0.04 | 0.25 ± 0.08 |
(1) 0–2.5 mU/L; (2) >2.5 mU/L; _1—results during the first week of hospitalization; _12—results three months after admission to the hospital; BDI—Beck Depression Inventory; Calgary—Calgary Depression Scale for Schizophrenia; CTQ—Childhood Trauma Questionnaire; CTQ_EA—emotional abuse; CTQ_EN—emotional neglect; CTQ_PA—physical abuse; CTQ_PN—physical neglect; CTQ_SA—sexual abuse; CTQ_TOTAL—total trauma; DUP—duration of untreated psychosis; FT3—free triiodothyronine; FT4—free thyroxin; HCT—hematocrit; HGB—hemoglobin; LYMP—lymphocytes; MCH—mean corpuscular hemoglobin; MCHC—mean corpuscular hemoglobin concentration; MCV—mean corpuscular volume; MONO—monocytes; MPV—mean platelet volume; NEUT—neutrophils; PANSS—Positive and Negative Syndrome Scale; PANSS pos—positive symptoms; PANSS neg—negative symptoms; PANSS dis—disorganized thoughts; PANSS exc—uncontrolled hostility/excitement; PANSS emo—anxiety/depression; PCT—platelet count; PDW—platelet distribution width; PLCR—platelet larger cell ratio; PLT—platelets; RBC—red blood cells; RDW—red blood cell distribution width; WBC—white blood cells.